Breaking News, Financial News

ICON

Central lab business expands, but revenues need to catch up.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ICON 3Q10 3Q10 Revenues: $225 million (+2%) 3Q10 Earnings: $20 million (-17%) YTD Revenues: $668 million (+1%) YTD Earnings: $65 million (-4%) Comments: Currency fluctuations knocked five points off of ICON’s quarterly revenue growth. The clinical business posted gross new business awards of $317 million and net bookings of $225 million. The company has undertaken cost reduction actions recently and plans further moves along that line....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters